Stonepine Capital Management LLC Invests $795,000 in Geron Corporation $GERN

Stonepine Capital Management LLC bought a new position in Geron Corporation (NASDAQ:GERN) in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 500,000 shares of the biopharmaceutical company’s stock, valued at approximately $795,000. Geron makes up about 0.8% of Stonepine Capital Management LLC’s holdings, making the stock its 27th largest holding.

A number of other hedge funds have also modified their holdings of the stock. Frisch Financial Group Inc. raised its holdings in shares of Geron by 84.3% in the 1st quarter. Frisch Financial Group Inc. now owns 19,025 shares of the biopharmaceutical company’s stock worth $30,000 after buying an additional 8,700 shares in the last quarter. Bank of Montreal Can raised its holdings in shares of Geron by 38.9% in the 4th quarter. Bank of Montreal Can now owns 33,147 shares of the biopharmaceutical company’s stock worth $117,000 after buying an additional 9,277 shares in the last quarter. Integrated Wealth Concepts LLC acquired a new position in shares of Geron in the 4th quarter worth approximately $36,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in shares of Geron by 3.1% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 384,411 shares of the biopharmaceutical company’s stock worth $1,354,000 after buying an additional 11,652 shares in the last quarter. Finally, Legal & General Group Plc raised its holdings in shares of Geron by 2.5% in the 4th quarter. Legal & General Group Plc now owns 508,872 shares of the biopharmaceutical company’s stock worth $1,801,000 after buying an additional 12,540 shares in the last quarter. 73.71% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on GERN shares. Scotiabank cut Geron from a “sector outperform” rating to a “sector perform” rating and dropped their target price for the stock from $4.00 to $1.50 in a report on Thursday, May 8th. The Goldman Sachs Group started coverage on Geron in a report on Thursday, July 10th. They set a “sell” rating and a $1.00 price target for the company. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, three have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $4.19.

Geron Trading Up 2.1%

GERN stock opened at $1.46 on Friday. The business has a fifty day moving average price of $1.36 and a 200 day moving average price of $1.56. Geron Corporation has a fifty-two week low of $1.09 and a fifty-two week high of $4.8250. The stock has a market capitalization of $931.50 million, a price-to-earnings ratio of -11.23 and a beta of 0.73. The company has a debt-to-equity ratio of 0.46, a current ratio of 7.87 and a quick ratio of 6.79.

Geron (NASDAQ:GERN) last released its quarterly earnings results on Wednesday, August 6th. The biopharmaceutical company reported ($0.02) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.03) by $0.01. Geron had a negative return on equity of 31.37% and a negative net margin of 53.52%.The firm had revenue of $49.04 million during the quarter, compared to analysts’ expectations of $47.30 million. During the same period last year, the firm posted ($0.10) EPS. The business’s revenue was up 5455.6% on a year-over-year basis. Analysts expect that Geron Corporation will post -0.25 EPS for the current fiscal year.

Geron Company Profile

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.